2 active not recruiting, 1 unknown, 1 withdrawn. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow OKN 007: new trials by email Literature Review of OKN 007 trials Research Report on OKN 007
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID - High-grade Glioma, Oligodendroglioma | Phase 1 | Active not recruiting | Oblato, Inc. | 16 | 2023-04-17 | 2024-11-29 |
| Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants OKN-007 - Glioblastoma, Astrocytoma | Phase 1 / Phase 2 | Withdrawn | Oblato, Inc. | 2022-08-01 | 2022-10-07 | |
| OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma OKN 007, Temozolomide, Photon/Proton IMRT - Glioblastoma | Phase 1 | Active not recruiting | University of Oklahoma | 27 | 2018-09-03 | 2026-09-18 |
| Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients OKN-007 - Recurrent Malignant Glioma | Phase 1 | Unknown | Oblato, Inc. | 31 | 2012-12-01 | 2023-03-29 |
Glioblastoma (3) · Glioma (3) · Astrocytoma (2) · Oligodendroglioma (2)
Oblato, Inc. (3) · University of Oklahoma (1)
United States (3)
James Battiste, MD (1) · James Battiste, MD, PhD (1)